Abstract
Peptide based vaccine design for cancer immunotherapy is currently being used in clinical trials for malignant melanoma with much success. Administration of synthetic peptides derived from proteins overexpressed in tumour cells (tumour-associated antigens) can elicit tumour-specific CD8+ T cell responses in vitro and in vivo. Currently, a number of tumour antigens from overexpressed cancer proteins such as mucin 1 (MUC1), survivin, carcinoembryonic antigen (CEA), telomerase reverse transcriptase (TERT) and HER- 2 / neu are examples of cancers whereby peptide based vaccinations are being tested for potential immunotherapy. In this review, we discuss some examples of the work being investigated with these cancer proteins, limitations to this therapy and suggestions of future directions to improve the efficacy of this treatment.
Keywords: peptide, cancer immunotherapy, tumour associated antigens, cytotoxic t cells, muc1
Letters in Drug Design & Discovery
Title: Peptide Based Vaccine Design for Cancer Immunotherapy
Volume: 1 Issue: 3
Author(s): D. S. Pouniotis, J. Halton and V. Apostolopoulos
Affiliation:
Keywords: peptide, cancer immunotherapy, tumour associated antigens, cytotoxic t cells, muc1
Abstract: Peptide based vaccine design for cancer immunotherapy is currently being used in clinical trials for malignant melanoma with much success. Administration of synthetic peptides derived from proteins overexpressed in tumour cells (tumour-associated antigens) can elicit tumour-specific CD8+ T cell responses in vitro and in vivo. Currently, a number of tumour antigens from overexpressed cancer proteins such as mucin 1 (MUC1), survivin, carcinoembryonic antigen (CEA), telomerase reverse transcriptase (TERT) and HER- 2 / neu are examples of cancers whereby peptide based vaccinations are being tested for potential immunotherapy. In this review, we discuss some examples of the work being investigated with these cancer proteins, limitations to this therapy and suggestions of future directions to improve the efficacy of this treatment.
Export Options
About this article
Cite this article as:
Pouniotis S. D., Halton J. and Apostolopoulos V., Peptide Based Vaccine Design for Cancer Immunotherapy, Letters in Drug Design & Discovery 2004; 1 (3) . https://dx.doi.org/10.2174/1570180043398894
DOI https://dx.doi.org/10.2174/1570180043398894 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
What are the Cancer Risks in BRCA Carriers Apart from Those Regarding the Breast and the Ovary?
Current Women`s Health Reviews ROS1 Kinase Inhibitors for Molecular-Targeted Therapies
Current Medicinal Chemistry Drug Repurposing in Human Cancers
Current Medicinal Chemistry Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Novel Next-Generation Sequencing and Networks-Based Therapeutic Targets: Realistic and More Effective Drug Design and Discovery
Current Pharmaceutical Design Cell-Penetrating Peptides: Mechanisms and Applications
Current Pharmaceutical Design Diagnostic Usage of Low Dose CT in Solitary Pulmonary Nodule Follow Up in Daily Practice
Current Medical Imaging Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Plants vs. Cancer: A Review on Natural Phytochemicals in Preventing and Treating Cancers and Their Druggability
Anti-Cancer Agents in Medicinal Chemistry Ceramide and Apoptosis: Exploring the Enigmatic Connections between Sphingolipid Metabolism and Programmed Cell Death
Anti-Cancer Agents in Medicinal Chemistry Polyelectrolyte Multilayer Films: From Physico-Chemical Properties to the Control of Cellular Processes
Current Medicinal Chemistry Matching Chelators to Radiometals for Positron Emission Tomography Imaging- Guided Targeted Drug Delivery
Current Drug Targets Bladder Cancer Stem Cells
Current Stem Cell Research & Therapy Identification and Characterization of BRCA1 and BRCA2 Founder Mutations
Current Women`s Health Reviews Editorial Review 2015
Current Radiopharmaceuticals Targeting EZH2 for Cancer Therapy: Progress and Perspective
Current Protein & Peptide Science The Sodium-Iodide Symporter
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Immunoglobulin VH Domains and Beyond Design and Selection of Single-Domain Binding and Targeting Reagents
Current Pharmaceutical Biotechnology Autophagy Fails to Alter Withaferin A-Mediated Lethality in Human Breast Cancer Cells
Current Cancer Drug Targets The Long and Winding Road to Cancer Treatment: The Trail System
Current Pharmaceutical Design